| 09/14/2026 6:24 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/14/2026 6:04 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/11/2026 9:30 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/10/2026 9:31 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/10/2026 7:53 AM | GLAXOSMITHKLINE CAPITAL INC (1224462) Filer GSK (1131399) Filer | Form 424B2 Transaction specifc information for a delayed shelf offering | |
| 09/10/2026 5:09 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/09/2026 9:45 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/09/2026 9:31 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/09/2026 5:19 AM | GSK (1131399) Subject | Form FWP | |
| 09/08/2026 8:06 AM | GLAXOSMITHKLINE CAPITAL INC (1224462) Filer GSK (1131399) Filer | Form 424B2 Transaction specifc information for a delayed shelf offering | |
| 09/08/2026 7:27 AM | GLAXOSMITHKLINE CAPITAL INC (1224462) Filer GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for GSK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.
|
| 09/01/2026 11:26 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:46 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/26/2026 9:37 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/24/2026 9:35 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/24/2026 5:57 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/24/2026 5:20 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/20/2026 10:19 AM | GSK (1131399) Subject Martinez Maria E (1761768) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/18/2026 9:34 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/13/2026 3:32 PM | GSK (1131399) Filer | Form 13F-HR Initial Quarterly Form 13F Holdings report filed by institutional managers | |
| 08/13/2026 10:33 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/11/2026 10:03 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/03/2026 10:16 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/30/2026 11:25 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/22/2026 11:52 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/20/2026 9:13 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/17/2026 6:14 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/17/2026 5:50 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/16/2026 9:45 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/15/2026 8:11 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/15/2026 8:00 AM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-T/A | |
| 07/14/2026 10:20 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/13/2026 10:28 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/13/2026 5:29 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/10/2026 7:44 AM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-T/A | |
| 07/10/2026 7:13 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/09/2026 10:27 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/09/2026 6:27 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/07/2026 3:44 PM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-T/A | |
| 07/01/2026 9:02 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 9:25 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Gold Miners Post Record Cash Flow Even as Prices Pull Back (Ad) The four largest gold miners are generating record free cash flow, even with gold pulling back from recent highs. Margins as high as 75 percent make this the most profitable stretch in their history.
Yet junior gold miners, the prime buyout targets for these cash-rich majors, are still priced as if gold were stuck at 1800 dollars an ounce instead of today's levels.
Analyst Garrett Goggin calls this the Golden Anomaly, a gap he says rarely lasts long once a gold bull market gets going. See the junior gold miners poised for a major buyout wave |
| 06/29/2026 9:20 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/26/2026 9:02 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/24/2026 3:03 PM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-T/A | |
| 06/24/2026 9:39 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/24/2026 9:46 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/24/2026 6:15 AM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-T | |
| 06/23/2026 10:05 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/22/2026 10:00 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/17/2026 11:20 AM | GSK (1131399) Filer | Form 11-K Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d) | |
| 06/17/2026 11:02 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/17/2026 11:04 AM | GSK (1131399) Filer | Form 11-K Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d) | |
| 06/15/2026 9:02 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/12/2026 5:32 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/11/2026 9:42 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/10/2026 3:54 PM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-C | |
| 06/10/2026 9:36 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/09/2026 4:20 PM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-C | |
| 06/09/2026 12:37 PM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/09/2026 6:13 AM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-C | |
| 06/09/2026 5:18 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 9:46 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 9:00 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/28/2026 5:02 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/27/2026 9:34 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 9:23 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 9:17 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/22/2026 6:19 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/20/2026 9:39 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/20/2026 9:40 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/19/2026 10:01 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 10:03 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 5:29 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/14/2026 3:45 PM | GSK (1131399) Filer | Form 13F-HR Initial Quarterly Form 13F Holdings report filed by institutional managers | |
| 05/14/2026 11:22 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/11/2026 9:59 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/11/2026 5:42 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/11/2026 5:31 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/06/2026 12:52 PM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/06/2026 10:18 AM | FMR LLC (315066) Filed by GSK (1131399) Subject | Form SCHEDULE 13G | |
| 05/05/2026 11:54 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 10:08 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 10:11 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/29/2026 11:00 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/29/2026 7:09 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/28/2026 10:18 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/28/2026 6:24 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/27/2026 7:13 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/27/2026 5:58 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/24/2026 10:20 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/23/2026 5:03 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Why major institutions are piling into this digital asset now (Ad) BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid.
The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. Get the name, the ticker, and exactly how to buy it |
| 04/22/2026 5:06 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/21/2026 5:03 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 11:46 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 5:37 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 5:19 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/17/2026 5:16 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/16/2026 12:01 PM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/16/2026 5:42 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/15/2026 5:39 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |